Assenagon Asset Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Assenagon Asset Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-69,931	Closed	-$61K	–	1173
2019 Q2	$61K	Hold	69,931	–	–	﹤0.01%	973
2019 Q1	$162K	Hold	69,931	–	–	﹤0.01%	901
2018 Q4	$162K	Sell	69,931 -41,637	-37%	-$367K	﹤0.01%	968
2018 Q3	$1.65M	Buy	+111,568	New	+$1.77M	0.02%	557

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Assenagon Asset Management's SNNA Position: Q3 2019 in Review

Assenagon Asset Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 69,931 shares — an estimated $61K sold.

Assenagon Asset Management first reported a position in SNNA in Q3 2018 and held it in 4 quarters. The position peaked at $1.65M in Q3 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Assenagon Asset Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Assenagon Asset Management sold 69,931 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $61K.
Assenagon Asset Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2018 and held it in 4 quarters.
Assenagon Asset Management's Sienna Biopharmaceuticals, Inc. position peaked at $1.65M in Q3 2018.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Assenagon Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.